Abstract: A circuit for collecting a blood component includes a blood collection device provided with a blood collection needle through which blood is collected from a blood donor, a blood separator in which the blood collected by the above blood collection device is separated, a blood component collection bag in which a predetermined blood component separated by the above blood separator is collected, a blood line in which the blood collection needle is connected to an inlet of the blood separator, a line for removing an initial blood flow, which branches from a first branching portion formed in the blood line, and in which an initial flow of blood collected from the blood donor is removed, and an anticoagulant-injection line that branches from a second branching portion, formed in the line for removing the initial blood flow, and into which an anticoagulant is injected.

Abstract: Devices, systems, and methods are disclosed herein for modulating the levels of one or more target components in the blood and/or lymph of a vertebrate subject for treatment of a disease or condition in the vertebrate subject. An implantable device is provided which includes a body defining at least one lumen configured for fluid flow; at least one first reservoir in communication with at least one lumen; one or more energy sources configured to provide energy to elicit one or more signal responses associated with one or more labels that bind to one or more target components in one or more of blood fluid or lymph fluid of the vertebrate subject; one or more sensors configured to detect the one or more signal responses associated with one or more labeled target components; and one or more reactive components in communication with the at least one lumen for release responsive to the one or more sensors.

Abstract: Devices, systems, and methods are described herein for controlling or modulating the levels of one or more target components in the blood and/or lymph of a vertebrate subject. Devices and systems are provided that include a body defining at least one lumen configured for fluid flow; at least one controllable flow barrier to fluid flow into the at least one lumen; at least one first reservoir disposed within the body and configured to include one or more bifunctional tags, wherein the one or more bifunctional tags are configured to selectively bind to one or more target components in one or more of blood fluid or lymph fluid of a vertebrate subject; at least one treatment region disposed within the at least one lumen; and at least one second reservoir disposed in the at least one treatment region and configured to include one or more reactive components, wherein the one or more reactive components are configured to sequester the one or more bifunctional tags when bound to the one or more target components.

Abstract: Methods and devices for selectively removing an agent from a physiological site, e.g., a physiological efferent fluid collection site, are provided. Aspects of the invention include fluid removal (e.g., aspiration) devices having a fluid removal element and a flow modulator positioned at a distal end of the fluid removal element. The flow modulator is configured to converge intersecting fluid flow paths into the fluid removal element. Also provided are systems and kits for performing the subject methods. The subject invention finds use in a variety of different applications, including the selective removal of both therapeutic and diagnostic agents from a variety of different physiological sites.

Abstract: An apparatus for carrying out selected fluid management and/or renal replacement patient therapy is characterized by an interactive operator control system having operator inputs for selectively changing a panel kit, replacing a filter cartridge, and/or changing to a different patient therapy during a currently running patient therapy, and providing operator instructions for carrying out tasks for completing same. In one embodiment, the interactive operator control system is also characterized by automatically serially identifying different setup steps to be carried out during system setup, displaying the successive steps substantially throughout the system setup as well as displaying on the operator interface screen sequential tasks to be carried out for each of the different setup steps.

Abstract: An optical blood monitoring system with a ratiometric model determines hematocrit values for a hemodialysis patient, from which hemoglobin values for the patient are estimated. The ratiometric model is calibrated, normally against a cell counter, using blood from a blood bank. The blood from a blood bank is preserved in a long term preservative which is typically different than that found in clinical settings. The hematocrit value determined by the ratiometric model is scaled by scaling factor so that the estimated hemoglobin level output from the monitor consistently matches that measured in a clinical setting. The hematocrit scaling factor is substantially about 1.033 when the patient's blood sample is stored in a short term preservative ethylene diamine tetra acetic, and is substantially about 1.06 when the hematocrit is measured in the blood sample without preservative being added to the blood sample. The hemoglobin value can also be adjusted for altitude.

Abstract: A hemodialysis apparatus includes a blood processing machine, a blood circuit through which blood led from a patient flows, a blood pump attached to the blood circuit to pump blood, a dialysate circuit, a clamp disposed downstream of the blood pump for the blood circuit to block the blood circuit, a blood pressure sensor for detecting the pressure of a part of the blood circuit between the blood pump and the blocker, and a control unit connected with the blood pump and the blood pressure sensor. The control unit is configured to determine, based on the pressure detected by the blood circuit pressure detector, whether or not the blood circuit has encountered abnormal conditions while the blood circuit blocked by the clamp is filled with liquid by the blood pump (steps SA2, SA3, and SA5).

Abstract: A device, system and method for exchanging components between first and second fluids by direct contact in a microfluidic channel. The fluids flow as thin layers in the channel. One of the fluids is passed through a filter upon exiting the channel and is recycled through a secondary processor which changes the fluid's properties. The recycled fluid is reused for further exchange. The filter excludes blood cells from the recycled fluid and prevents or limits clogging of the filter. The secondary processor removes metabolic waste and water by diafiltration.

Abstract: Devices, systems, and methods are described herein for controlling or modulating the levels of one or more target components in the blood and/or lymph of a vertebrate subject. Devices and systems are provided that include a body defining at least one lumen configured for fluid flow; at least one controllable flow barrier to fluid flow into the at least one lumen; at least one first reservoir disposed within the body and configured to include one or more bifunctional tags, wherein the one or more bifunctional tags are configured to selectively bind to one or more target components in one or more of blood fluid or lymph fluid of a vertebrate subject; at least one treatment region disposed within the at least one lumen; and at least one second reservoir disposed in the at least one treatment region and configured to include one or more reactive components, wherein the one or more reactive components are configured to sequester the one or more bifunctional tags when bound to the one or more target components.

Abstract: A system or method controls total fluid loss (TFL) in a patient undergoing hemofiltration therapy administered through an extracorporeal circuit by frequently calculating and storing a retrievable value representing TFL. At session start or restart, the value is read to determine whether TFL is out of tolerance, and if so, fluid balance is restored before administering a prescribed therapy. The TFL value is calculated during therapy by measuring fluid added to the circuit and fluid removed from the circuit, and the result is stored as an updated value. If TFL drifts out of tolerance fluid flow rates may be temporarily changed until a desired fluid balance is restored. The system may include a microprocessor based advanced controller receiving the fluid measurements as feedback for regulating substitution fluid and filtrate flow rates, and updating the TFL, value in non-volatile memory.

Abstract: The invention relates to a calculation and control system for determining whether a patient intended to follow several sessions of hemodialysis treatment falls or not within one group among several groups of hypertension-affected patients, the system comprising: a) means for determining the value of at least one parameter representing the mass interdialytic evolution of the patient, for at least two sessions, b) means for determining the value of at least one parameter representing the plasmatic conductivity of the patient for at least two sessions, c) means for determining the value of a parameter representing the ionic mass transfer of the treatment for at least two sessions, d) programmed means for determining whether the patient falls or not within a group of hypertension-affected patients as a function of the interdialytic mass evolution of the patient, and/or of the plasmatic conductivity and/or of the ionic mass transfer.

Abstract: One or more waste balancing systems may be used in a fluid circulating system for medical use. The fluid circulating system may be part of a blood treatment system for a patient suffering renal failure. A waste balancing system may include a pressure element operable to maintain a constant fluid pressure created by the combined weight of waste removed from a patient and replacement fluid for providing to a patient. Multiple evaluation characteristics or control parameters may be evaluated or controlled for safety and accuracy. At least part of the waste balancing system may be incorporated into a disposable cartridge.

Abstract: The present invention includes a comprehensive replacement fluid system and method for the delivery of regional citrate anticoagulation (RCA) to extracorporeal blood circuits, wherein the system may include an online clearance monitor (OCM) and a circuit effluent online sensor system (OSS) for the continuous determination of patient plasma content of ultrafilterable soultes.

Abstract: Blood filtering device (1), comprising: * a filter body (3; 103), having an inlet port (4; 104) for blood to be filtered; * a delivery flexible hose (5; 105) of the blood to be filtered, apt to be connected to said inlet port (4; 104) and to further ducts linked to a circulatory system; * peristaltic pump means (10; 105, 109, 114, 115, 117, 118, 143, 144, 145), wherein a case (16; 116) forms at least one peristaltic pump rotor chamber (13; 114), apt to house inside a portion of said delivery flexible hose (5; 105) for obtaining a peristaltic effect, wherein said case (16; 116) defines means for maintaining said filter body (3; 103) in a working position.

Abstract: The invention is directed to a method of removing a deleterious substance bound to a protein in blood of a patient by introducing a displacer substance into the blood under conditions in which the displacer substance replaces deleterious substance bound to the protein, thereby resulting in additional unbound deleterious substance in the blood, and removing unbound deleterious substance from the blood by extracorporeal renal replacement treatment.

Abstract: A novel system and method for fluid management for accurate continuous venovenous hemofiltration (CWH) in extracorporeal membrane oxygenation (ECMO). The fluid management or CWH system is automated and configured for operation as a stand alone unit and can be easily integrated with an ECMO system. The fluid management system is capable of producing either perfect or negative fluid balance between ultrafiltrate removal and replacement fluid delivery. The fluid management system can achieve electrolyte replacement over a range of flow rates needed to care for patients ranging from neonates to adults. Finally, the novel fluid management system preserves patient safety, maintains sterility during operation, is easy to operate, and is compact enough to fit near a patient's bed.

Abstract: The present invention relates to an ocular implant, particularly a glaucoma stent. It is the object of the present invention to devise an ocular implant which allows the ocular eye pressure to be regulated, i.e., to be maintained at a desired level, while preventing the flow resistance from increasing over time, for example due to fibrosis. In order to achieve this object, the ocular implant according to the invention comprises a small tube (5), the wall surface (3) of which encloses a hollow duct that is open on both sides in the longitudinal direction of the hollow duct, wherein a first opening (1) allowing ocular humor to flow in and a second opening (2) allowing the ocular humor to be discharged is provided, and wherein the wall surface (3) is formed by a liquid-tight material, and wherein at least one pressure-controlled valve (4) is disposed in the area of the wall surface (3).

Abstract: An ultrafiltration device adapted to be worn on a portion of the body of a patient includes a blood inlet tube leading from a first blood vessel, a blood pump, an anticoagulant reservoir for infusing anticoagulants into the blood, a blood filter including a substrate through which the blood is circulated and filtered, a fluid bag for storing the excess fluid and a blood outlet tube leading to a second blood vessel.

Abstract: The present application relates to a system and method for treating carbon monoxide poisoning. The system and method comprises passing the blood of a subject in need of such treatment through a filter unit comprising a gas permeable membrane to remove carbon monoxide from the blood by filtration against an extraction fluid enriched with oxygen and/or by exposure to one or more agents suitable for removing carbon monoxide or converting carbon monoxide to carbon dioxide, which is more readily exchangeable with oxygen compared to carbon monoxide.

Abstract: A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors. In the preferred embodiment, the patient is ultrapheresed using a capillary tube ultrafilter having a pore size of 0.02 to 0.05 microns, with a molecular weight cutoff of 120,000 daltons, sufficient to filter one blood volume. The preferred replacement fluid is ultrapheresed normal plasma. The patient is preferably treated daily for three weeks, diagnostic tests conducted to verify that there has been shrinkage of the tumors, then the treatment regime is repeated. The treatment is preferably combined with an alternative therapy, for example, treatment with an anti-angiogenic compound, one or more cytokines such as TNF, gamma interferon, or IL-2, or a procoagulant compound. The treatment increases endogenous, local levels of cytokines, such as TNF.

Abstract: A method for batch implementation of settings in a renal replacement therapy device including: displaying on a user interface control settings which may be manually selected by an operator; selecting an independent control setting of the plurality of control settings; adjusting the independent control setting to an independent control setting level selected by an operator; temporarily storing the adjusted independent control setting level; automatically adjusting a dependent control setting level based upon the independent control level; displaying the adjusted independent control setting level and the adjusted dependent control setting, and implementing both the adjusted independent control setting level and the adjusted dependent control setting to control the device, by actuating a batch setting acceptance operation.

Abstract: The present invention provides a dialysis machine that is readily moved by a patient, nurse or other operator. A display is provided on the front of the machine, which displays and controls various dialysis functions. The display is robust, mounted directly to the body and includes an open area that can be grasped by a person to move the entire machine. The combination display/handle enables the person to move the machine from the front of same and from odd angles with respect to the machine.

Abstract: An extracorporeal blood system includes: an extracorporeal blood machine including an extracorporeal blood circuit; an access device enabling the extracorporeal blood circuit to be connected to a patient; first and second tube connecting members for connecting respectively to first and second tubes of the extracorporeal circuit; first and second electrodes held, at least in part, by the first and second tube connecting members so as to contact blood flowing through the extracorporeal blood circuit, the first and second electrodes enabling an electrical signal to be injected into the extracorporeal blood circuit; first and second contact members contacting the first and second electrodes respectively; and electronics coupled operably to the first and second contact members for applying the electrical signal, the signal used to monitor the access device.

Abstract: An ultrafiltration device adapted to be worn on a portion of the body of a patient includes a blood inlet tube leading from a first blood vessel, a blood pump, an anticoagulant reservoir for infusing anticoagulants into the blood, a blood filter including a substrate through which the blood is circulated and filtered, a fluid bag for storing the excess fluid and a blood outlet tube leading to a second blood vessel.

Abstract: Hemodialysis systems and methods with streamlined blood flow paths are provided. Such streamlined blood flow paths facilitate flow without undue damage to circulating cells.

Abstract: The present invention includes a comprehensive replacement fluid system and method for the delivery of regional citrate anticoagulation (RCA) to extracorporeal blood circuits, wherein the system may include an online clearance monitor (OCM) and a circuit effluent online sensor system (OSS) for the continuous determination of patient plasma content of ultrafilterable solutes.

Abstract: A patient wearable, continuously operating extracorporeal pump apparatus which accesses the patient's arterial venous pressure differential by applying external pressure to a subcutaneous graft that has been cannualized to modulate blood flow through an extracorporeal circuit and to drive the pump for delivering a medicament, such as an anticoagulant, to the site of an intravenous cannula to prevent clogging thereof and also to move a dialysate through a circuit, including a dialyzer and a dialysate rejuvenating cartridge, whereby kidney failure can be treated without recourse to prior art hemodialysis machines found in most treatment facilities. With slight modification, the present invention can be used to remove excess fluids from CHF patients, to remove toxins from the blood in those suffering from liver failure and to facilitate administration of insulin to diabetics and/or glucose to those having hypoglycemia.

Abstract: A dialysis system includes a dialysis instrument including at least one pump actuator; a disposable cassette operable with the at least one pump actuator; a plurality of supply containers connected fluidly to the disposable cassette; and a cart which includes a rotatable bearing plate onto which the instrument and supply containers are loaded, the bearing plate allowing a patient to turn the instrument and supply containers relative to the cart for selective access to the instrument or the supply containers.

Abstract: A machine (1) for extracorporeal blood treatment comprises a device (2) for ultrafiltration of a liquid through a semi-permeable membrane (3) of a blood treatment device (4), a first sensor (11) for ultrafiltration rate through the membrane, a second group of sensors (13) for measuring a trans-membrane pressure, and a programmed controller (14) for calculating a maximum ultrafiltration rate as a function of the transmembrane pressure. The machine is suitable for kidney failure treatments, such as hemofiltration and hemodiafiltration. In a relatively short time the machine enables a large quantity of corporeal blood to be removed from the patient.

Abstract: To accomplish isolation and removal of a substance from a vasculature, a catheter is employed to occlude a vessel of the vasculature. The substance is thus isolated in the vasculature and can be removed. In this way, the substance is removed before entering other parts of the circulatory system. This method is applicable to removal of contrast from the coronary sinus shortly after injection of the coronary arteries with the contrast. The method substantially minimizes or avoids renal dysfunction caused by angiographic procedures in which contrast must be injected. Such angiographic procedures are often performed during intervention procedures. This method substantially prevents circulation of the contrast to the kidneys where it could otherwise cause renal dysfunction or failure. The apparatus for implementation of the method is also disclosed.

Abstract: A device, system and method for exchanging components between first and second fluids by direct contact in a microfluidic channel. The fluids flow as thin layers in the channel. One of the fluids is passed through a filter upon exiting the channel and is recycled through a secondary processor which changes the fluid's properties. The recycled fluid is reused for further exchange. The filter excludes blood cells from the recycled fluid and prevents or limits clogging of the filter. The secondary processor removes metabolic waste and water by diafiltration.

Abstract: A device, system and method for exchanging components between first and second fluids by direct contact in a microfluidic channel. The fluids flow as thin layers in the channel. One of the fluids is passed through a filter upon exiting the channel and is recycled through a secondary processor which changes the fluid's properties. The recycled fluid is reused for further exchange. The filter excludes blood cells from the recycled fluid and prevents or limits clogging of the filter. The secondary processor removes metabolic waste and water by diafiltration.

Abstract: The present invention is directed to devices, systems and methods for removing undesirable materials from a sample fluid by contact with a second fluid. The sample fluid flows as a thin layer adjacent to, or between, concurrently flowing layers of the second fluid, without an intervening membrane. In various embodiments, a secondary separator is used to restrict the removal of desirable substances and effect the removal of undesirable substances from blood. The invention is useful in a variety of situations where a sample fluid is to be purified via a diffusion mechanism against an extractor fluid. Moreover, the invention may be used for the removal of components from a sample fluid that vary in size. When blood is the sample fluid, for example, this may include the removal of ‘small’ molecules, ‘middle’ molecules, macromolecules, macromolecular aggregates, and cells, from the blood sample to the extractor fluid.

Abstract: A dialysis fluid system includes an instrument including a pump actuator and a fluid heater, and a dialysis fluid cassette. The dialysis fluid cassette includes a rigid portion defining a pumping section for operation with the pump actuator and a heating section for operation with the fluid heater. The heating section includes a dialysis fluid inlet, a dialysis fluid outlet, and a dialysis fluid heating area located between the fluid inlet and the fluid outlet, the heating section further includes an air separation chamber for collecting air separated from the dialysis fluid.

Abstract: A medical apparatus (1) comprises a user interface (30), a number of sensors (16,27,21,22,29) and a control system (18) programmed for displaying on the user interface screen (31) a number of indicia (37), each relating to a corresponding parameter and comprising an indicium border (45) delimiting an indicium selection area (45a); the control system allows selection of an indicium for identifying the parameter a user intends to modify, allows setting of a new set value for the selected parameter; the control system also receives from the sensors (29) a measure of the actual value for the parameter and displays on the indicium selection area (45a) of the indicium both the actual value and the set value for the same parameter. The programming software for the control system is also disclosed.

Abstract: A device for continuously measuring osmotic pressure of blood flowing through an extracorporeal blood circuit including: a blood passage further comprising a withdrawal blood passage connectable to a blood vessel in a patient and an infusion blood passage connectable to a blood vessel in a patient; a filter further comprising a filtrate chamber, a blood chamber and a permeable membrane separating the filtrate chamber and blood chamber, wherein the blood chamber is in fluid communication with the blood passage; a pressure sensor measuring a pressure difference between the filtrate chambers and the blood chamber, and a controller receiving a pressure signal from the pressure sensor, determining an osmotic pressure across the permeable membrane of the filter, and adjusting a rate of removal of fluid from blood in the filter if the determined osmotic pressure level varies from a predetermined osmotic pressure setting.

Abstract: Methods and devices are provided for the extracorporeal ablation of target cells circulating in blood of an organism. Exogenous material introduced into the blood preferentially associates with target cells (e.g. cancer cells, bacteria, viruses) in the blood. An extracorporeal continuous flow pathway accesses the patient's blood to apply an external energy source to the blood at an ex vivo ablation device in a portion of the extracorporeal continuous flow pathway. The exogenous material interact with the applied energy so as to result in the damage or death of the target cells. The blood is then returned to the body in a continuous-flow pattern. By applying the energy while the blood is in the ex vivo ablation device, shielding of the target cells by the body is reduced and detrimental effects on the organs and tissues of the body are avoided or mitigated.

Abstract: The invention provides container systems, kits and methods for peritoneal dialysis (PD) solutions. Such a system, for example, includes a first compartment that contains a PD osmotic agent and a second compartment that contains a PD buffer agent. The compartments maintain their respective contents separately from one another for purposes of transport, storage and/or sterilization. However, the compartments are fluidly couplable, so that their respective contents can be combined with one another, e.g., following sterilization of the agents and prior to their introduction into the patient's abdomen. The invention provides, in other aspects, such systems, kits and methods that provide protective structure which inhibits breaking of a seal prior between the second compartment and an outlet of the system, prior to breaking of a seal between the first and second compartments.

Abstract: A method and a device to increase the efficiency of dialysis for the removal from blood of substances that are more or less tightly bound to carriers such as albumin. According to the invention this is accomplished by a simultaneous significant increase of the flow rate of the dialysis fluid and of the area of the membrane that separates the blood from the dialysis fluid, compared to conventional dialysis.

Abstract: An extracorporeal circuit for removing toxins from the blood and plasma volume control in patients suffering from sepsis and renal failure. The extracorporeal circuit disclosed herein comprises a plasma filter, a toxin removal device and optionally a hemofilter that minimizes electrolyte and protein depletion from the treated plasma while effectively removing both free and protein-bound toxins. The toxin removal device comprises adsorbent materials selected from the group consisting of activated carbon, ion exchange resins and non-ionic exchange resins and the adsorbent materials are coated with albumin. Also provided are associated methods for treating patients suffering from sepsis and renal failure using the disclosed extracorporeal circuit and toxin removal device.

Abstract: Arrangement for extracorporeal circulation of blood having a generally uniform flow diameter where the risk for stagnation of blood is avoided or reduced. The arrangement comprises a generally circular cylindrical means for temporary expanding the flow diameter, a means for flow expansion (9). The means for flow expansion (9) is arranged connecting the bloodline (5) and a component (6, 8) for circulation of the blood. The means for flow expansion (9) comprises a first part with a first flow diameter, d1 and a second part downstream the first part with a second flow diameter d2 where d2/d1?1.5. The first part has a length extension L1 and the second part has a length extension L2 where L2/L1?0.5.

Abstract: The present invention is directed to devices, systems and methods for removing undesirable materials from a sample fluid by contact with a second fluid. The sample fluid flows as a thin layer adjacent to, or between, concurrently flowing layers of the second fluid, without an intervening membrane. In various embodiments, a secondary separator is used to restrict the removal of desirable substances and effect the removal of undesirable substances from blood. The invention is useful in a variety of situations where a sample fluid is to be purified via a diffusion mechanism against an extractor fluid. Moreover, the invention may be used for the removal of components from a sample fluid that vary in size. When blood is the sample fluid, for example, this may include the removal of ‘small’ molecules, ‘middle’ molecules, macromolecules, macromolecular aggregates, and cells, from the blood sample to the extractor fluid.

Abstract: A haemodialysis device having an emergency activating function is provided. In order to avoid critical drops in blood pressure during a dialysis treatment, the emergency activating function makes it possible for the operating staff to initiate with a single control function a blood pressure measurement and a delivery of substance into the patient's blood in the event of a hypotensive episode and at the same time to have the introduction of these measures by the haemodialyser confirmed clearly through a display having an outward appearance different from that displayed during normal operations. In addition, further automatically introduced process steps can be provided. The emergency activating function speeds up the implementation of the measures to be introduced and, at the same time prevents incorrect operation and makes it possible for the operating staff to attend directly to the patient.

Abstract: The present invention provides a bilirubin reducing means which can minimize a risk such as the onset of an infection or the occurrence of blood coagulation and can reduce physical, temporal and economical burdens imposed on a patient suffering from liver dysfunction.

Abstract: A method and a hemodialysis machine provide for at least partial emptying of an extracorporeal blood circulation after patient blood in the circulation has been returned to the patient via an infusion liquid which displaces the blood. The method includes emptying at least a blood chamber of a hemodialyzer subdivided by a semipermeable membrane into the blood chamber and a dialysis fluid chamber without additionally connecting an arterial blood line and a venous blood line of the circulation to one another. The arterial blood line is actively or passively aerated at a first point and the venous blood line is actively or passively aerated at a second point. The infusion liquid is emptied through the membrane into the dialysis fluid chamber and then via a dialysis fluid discharge line. The method is operable by a control program that runs automatically without requiring any manual input after activation of the program.

Abstract: The dose of dialysis in terms of urea clearance is marginal in many hemodialysis patients, and metabolic acidosis as determined by the pre-dialysis serum HCO3 level is common. A dialysate that included citric acid rather than acetic acid as acidifying agent provides superior performance properties. Citrate-containing dialysate was used exclusively in 22 hemodialysis patients. Initially, only 8 of the 22 patients had a pre-dialysis serum HCO3>23 mEq/L (lower limit of normal), however, after 12 weeks of dialysis using the citrate-containing dialysate, the serum HCO3 normalized in 15 patients (p=0.0001, Chi-square). Dialysis variables were kept constant in 19 of the patients, who also used and reused the same dialyzer model throughout. In these patients, the initial average urea reduction ratio (URR) was 68.5±5.9%, and after treatment with the citrate dialysate disclosed herein, this ratio had increased to 73±5.3% (p<0.03). SpKt/V, calculated using the Daugirdas II formula, also increased from 1.23±0.

Abstract: A peristaltic roller pump includes a rotor carrying a pumping roller on one end and an occluding roller on the other end. Occluding roller has a number of protrusions designed to occlude the tubing section that is located under that roller as it moves over it in order to prevent any back flow through that section of the tube. Occluding roller is designed to not cause any pumping of fluid through the section of the tubing under that roller. Such design is useful in a single-needle dialysis system in which during a first phase of pumping blood is moved in one direction from the patient towards the dialysis unit and during the second phase of operation blood is returned to the patient in the opposite direction.

Abstract: A blood purification apparatus includes a blood circuit, a blood purifying device, a driving device, an air bubble detection device, and a connection condition evaluation device. The blood circuit is provided with arterial and venous blood circuits, to which needles are attached at ends thereof. The blood purifying device is connected between the arterial and venous circuits. In a blood purifying treatment after a priming operation, the driving device drives the blood in the arterial blood circuit in a forward direction, and drives the blood in the venous blood circuit in a reverse direction. The air bubble detection device detects air bubbles in a liquid flowing in the arterial and venous blood circuits. The connection condition evaluation device evaluates connection conditions of the needles to the ends of the arterial and venous blood circuits based on the detection by the air bubble detection device.

Abstract: A switch valve for use in an extracorporeal blood flow circuit comprises a valve housing having a chamber, four openings communicating with the chamber, and a valve member located in the valve chamber. A first opening is to be connected to a patient via an arterial cannula, a second opening is to be connected to a patient via an venous cannula, a third opening is to be connected to a first inlet/outlet of a blood treatment device, and a fourth opening is to be connected to a second inlet/outlet of a blood treatment device. The valve member is movable within the valve housing to fluidly connect the first opening to either the third or the fourth opening and to fluidly connect the second opening to either the third or the fourth opening. The width of the valve member is smaller than a peripheral dimension of the openings.

Abstract: The invention relates to an apparatus and a method for the treatment of the blood in a Continuous Renal Replacement Therapy, using a machine which comprises: —connecting means from and to respective blood vessels of a patient; —blood processing means comprising a pump; —means for adding drugs or other therapeutic substances to the blood being treated; —means for feeding refill liquid into the blood; —blood filtration means, cascade-connected to one another by relative conduits, said conduits and said connecting means defining a blood path; wherein the blood to be treated passes through an oxygenating device which comprises an oxygenating membrane and is located upstream from said blood filtration means and downstream from said blood processing means, so that the blood is treated by said oxygenating membrane without the intake pressure along the portion upstream from the blood pump; and wherein the blood is pumped downstream from the connecting means to the oxygenating device at a flow rate of about 280-300 ml